March 23, 2022 7:57am

It’s the physiology of the cell and gene therapy sector

Pre-open indications: 8 SELLs, 3 BUYs and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

 


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are DOWN -0.29% (-99 points), S&P futures are DOWN -0.37% (-16 points) and NASDAQ futures are DOWN -0.60% (-88 points)

 

U.S. stock futures dipped in early morning trading on Wednesday, as traders hope to interpret the outlook for U.S. Fed’s monetary policy,

European stocks were hovering flat as U.K. inflation came in at an annual 6.2% in February, its highest since March 1992,

Asia Pacific stocks soared as most geographies closed higher

 

Henry’omics:

The ways of the morning dips: inflation, oil pricing, the Fed comments, rising mortgage rates, the war in Ukraine and coming-off a strong session and recession possibilities.

Economic Data Docket: new homes sales data from February will be released at 10 a.m. 

 

RegMed Investors’ (RMi) closing bell: “adjusting expectation, the monkey bars versus the slide. The cell and gene therapy sector regained ground on Tuesday as I stated this a.m., “Volatility puts sector on notice regulating directional motion” …  https://www.regmedinvestors.com/articles/12354

Ebb and flow –

·         March – 8 negative and 8 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

 

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  (CRBU) added, 29 total to date

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

SELL:

  • Agenus (AGEN) -0.04 or -1.43% pre-open indication
  • Bellicum Pharmaceuticals BLCM) -$0.10 or -4.88% pre-open indication
  • Global Blood Therapeutics (GBT) -0.17 or -0.50% pre-open indication
  • Mesoblast (MESO) -0.18 or -4.02% pre-open indication
  • Pluristem (PSTI) -$0.04 or -1.97% pre-open indication
  • uniQure NV (QURE) -$0.24 or -1.35% pre-open indication
  • Sage Therapeutics (SAGE) -$0.54 -1.55% pre-open indication
  • Sangamo therapeutics (SGMO) -0.16 or -2.62% pre-open indication

BUY:

  • Beam Therapeutics (BEAM) +$0.12 or +0.19% pre-open indication
  • Caribou Biosciences +$0.48 or +4.79% pre-open indication
  • Fate Therapeutics +$2.30 or +6.07% pre-open indication

Pimp/Pump and Promote:

  • Biostage (OTCQB: BSTG) closed down -$0.17 with 202 shares traded after Monday’s flat with 5 shares traded. WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?

 

The BOTTOM LINE: Never totally wrong but, not always wholly right after Tuesday’s dire warning that became baseless.

My thoughts go to Lincoln address as 3:30 a.m., opens my computer … “Four score and seven years ago our” …

Now we are engaged in a … war, testing whether that nation, or any nation so conceived and so dedicated”, can long endure these many issues of these recent times. We are met on a great battle-field of that” … politics and their actions. We have come to dedicate our portfolios to the future of the cell and gene therapy medications.

Sector equities ended higher on Tuesday, as shares of sector “names” rebounded from Monday’s losses and Nike rose after it reported upbeat results.

With the recent lows and highs, the wash-out equities highs and resulting lows because this market and sector remain at the mercy of the latest headline as war and killing news, Fed questions and the lack of positive sector news is the bane of March lifting or sinking the major indexes.

Caution is still in order. The sector showed strength (+9.51%% from +0.53%) some equities struggling (0.35%, -3.80%, -1.47% and 1 at 27.22%).

I say, cut or partially sell into strength without totally removing some names.

There are still plenty of hurdles i.e., as economy faces struggles, European war headlines - hopes of progress in talks between the two sides last week fading, and maybe further earnings surprises - another eight (8) are due.

There is no clear trend ….

Earnings’ reporting on the horizon:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.